M06-01: The predictive and prognostic roles of ERCC1 Expression and Akin DNA repair genes in non-small-cell lung cancer  by Rosell, Rafael
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS166
14 Takashima S, Maruyama Ya, Hasegawa Ma, et al. Prognostic signiﬁcance of high-reso-
lution CT ﬁndings in small peripheral adenocarcinoma of the lung: a retrospective study 
on 64 patients. Lung cancer 2002; 36: 289-295 
15 kakinuma R, Ohmatsu H, Kaneko K, et al. Progression of focal pure ground-glass 
opacity detected by low-dose Helical computed tomography screening for lung cancer. 
JCAT 2004; 28:17-23
16 Kishi K, Homma S, Kurosaki A, et al. Small lung tumors with the size of 1 cm or less 
in diameter: clinical, radiological, and histopathological characteristics. Lung Cancer 
2004; 44: 43-51
17 Lee HJ, Goo JM, Lee CH, et al. Nodular ground-glass opacities on thin-section CT: size 
change during follow-up and pathological results. Korean J Radiol 2007; 8: 22-31
18 Sakao Y, Miyamoto H, Sakuraba M, et al. Prognostic signiﬁcance of a histologic 
subtype in small adenocarcinoma of the lung: The impact of the nonbronchiloalveolar 
carcinoma component. Ann thorac Surg 2007; 83: 209-214
19 Ohtsuka T, Watanabe K, Kaj Mi, et al. A cliniclpathological study of resected pulmo-
nary nodukes with focal pure ground-glass opacity. Eur J Cardiothorac Surg: 2006: 
30:160-163
20 MacMahon H, Austin JHM, Gamsu G, et al. Guidelines for management of smallpul-
monary nodules detectd on CT scans: a statement from the Freischner society. Radiol-
ogy 2005; 237: 395-400
Session M06: Molecular Predictors and Prognosticators
M06-01  Molecular Predictors and Prognosticators, Mon, Sept 3, 10:30 - 12:00
The predictive and prognostic roles of ERCC1 Expression and 
Akin DNA repair genes in non-small-cell lung cancer
Rosell, Rafael 
Institut Catala d’Oncologia- Hospital Germans Trias i Pujol, 
Badalona, Spain
Cisplatin doublets remain the standard treatment for stage IV non-
small-cell lung cancer (NSCLC) patients. Large randomized studies 
have demonstrated the equivalence of several cisplatin doublets, includ-
ing gemcitabine and docetaxel, with meager response rates and gloomy 
survival outcomes, with median survival commonly less than one 
year(1). Intriguingly, response varied signiﬁcantly between individual 
patients(2), highlighting the need for molecular predictive markers for 
cisplatin and docetaxel response and survival in NSCLC.
NER, a highly versatile pathway for DNA damage removal, is often 
dysfunctional in NSCLC and could therefore be the Achilles heel for 
customizing chemotherapy. NER removes numerous types of DNA he-
lix-distorting lesions, including cisplatin- and ultraviolet-induced photo 
products(3). NER functions by a “cut-and-paste” mechanism in which 
cisplatin damage recognition, local opening of the DNA helix around 
the lesion, damage excision and gap-ﬁlling occur in successive steps(3) 
(Figure). NER is composed of two sub-pathways: global genome NER 
(GG-NER) and transcription-coupled NER (TC-NER) share the same 
core mechanism but differ in the way lesions are recognized. The 
structure-speciﬁc endonuclease excision repair cross-complementing 
1 (ERCC1) performs an essential late step in the NER process, where 
it nicks the damaged DNA strand at the 5’ site of the helix-distort-
ing cisplatin lesion. Importantly, the ERCC1/XPF structure-speciﬁc 
nuclease has an additional role in the repair of cisplatin adducts besides 
its function in NER: the recombinational repair of interstrand cross-
links(4). Moreover, co-localization of ERCC1 foci and RAD51 foci in 
response to cisplatin treatment has recently been found and may rep-
resent recruitment of ERCC1/XPF to sites of recombination repair(5). 
Previous studies have shown that BRCA1, involved in homologous 
recombination repair, also plays a major role in the repair of cisplatin 
DNA damage(6).
High tumor tissue levels of ERCC1 mRNA in ovarian and gastric 
cancer patients have been associated with cisplatin resistance(7, 8). 
Similarly, inhibition of ERCC1 expression has been signiﬁcantly as-
sociated with reduced HCR of cisplatin-treated cells and their increased 
cisplatin sensitivity(9, 10). Cisplatin resistance in NSCLC cell lines has 
also been related to the increase of HCR(11), and signiﬁcant differ-
ences in survival were observed in cisplatin-treated NSCLC patients 
according to their DRC(12). When intratumoral ERCC1 mRNA derived 
from parafﬁn-embedded tumor specimens was measured by real-time 
reverse transcriptase polymerase chain reaction (RT-PCR) in metastatic 
colon cancer patients treated with oxaliplatin and 5-ﬂuorouracil (5-FU), 
high levels of ERCC1 signiﬁcantly correlated with poor response and 
shorter survival(13). We observed longer survival and a trend toward 
improved response in gemcitabine/cisplatin-treated stage IV NSCLC 
patients with low ERCC1 mRNA levels(14). A higher response rate 
was observed in locally advanced NSCLC patients with low levels of 
ribonucleotide reductase subunit M1 (RRM1) and ERCC1 treated with 
induction gemcitabine/carboplatin(15). ERCC1 protein expression 
by immunostaining was associated with survival in NSCLC patients 
treated with cisplatin-based adjuvant therapy(16).
However, GG-NER, might not correctly detect cisplatin DNA adducts, 
since it has been shown to possess a low afﬁnity for these adducts(17, 
18). On the other hand, defects in TC-NER (Figure) render cells 
markedly hypersensitive to cisplatin(19). BRCA1-deﬁcient cells are 
hypersensitive to cisplatin(20). 
From August 2001 to October 2005, 444 stage IV NSCLC patients 
were enrolled in a Spanish Lung Cancer Group randomized trial of cus-
tomized chemotherapy based on ERCC1 mRNA levels. Patients in the 
control arm received docetaxel plus cisplatin. Patients in the genotypic 
arm received treatment based on ERCC1 mRNA levels: those with low 
levels received docetaxel plus cisplatin; those with high levels received 
non-cisplatin-based treatment (docetaxel plus gemcitabine). The pri-
mary endpoint was the overall objective response rate. Of the 444 pa-
tients enrolled in the study, 78 patients (17.6%) went off-study prior to 
receiving one cycle of chemotherapy. The main reason for withdrawal 
was insufﬁcient tumor tissue for ERCC1 mRNA assessment. Objective 
response was 39.3% in the control arm and 50.7% in the genotypic arm 
(P = .019). This study shows that assessment of ERCC1 mRNA expres-
sion is feasible in the clinical setting and predicts response to docetaxel 
plus cisplatin. Further studies are warranted to reﬁne a multi-biomarker 
proﬁle predictive of patient outcome. 
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RRM1 is the regulatory subunit of ribonucleotide reductase. It is cru-
cial for DNA synthesis and damage repair. In addition, high levels of 
RRM1 are associated with G2 cell cycle arrest and increased apoptosis 
in vitro. To assess its prognostic utility on lung cancer outcome in 
patients with complete surgical resection of NSCLC, we analyzed its 
level of expression by real-time quantitative RTPCR in prospectively 
collected fresh-frozen tumor specimens and independently in formalin-
ﬁxed and parafﬁn-embedded (FFPE) tumor specimens by quantitative 
in situ ﬂuorescence immunohistochemistry (AQUA). We found that 
RRM1 expression was directly correlated with survival; i.e., high levels 
of expression were prognostic of long survival. mRNA and protein 
expression levels of RRM1 were modestly but signiﬁcantly corre-
lated (JCO 22:1878, 2004; NEJM 356:800, 2007). Prior retrospective 
studies had suggested that patients with advanced stage NSCLC and 
high tumoral RRM1 levels that received gemcitabine-based double 
agent chemotherapy did worse than those with low RRM1 levels. This 
paradox has been explored through molecular biological studies in 
recent years. The results of these studies, which have been conducted 
in NSCLC (Cancer Res 64:3761, 2004; JCO 24:4731, 2006), colorectal 
cancer (Cancer Res 65:9510, 2005), and pancreatic cancer (Int J Cancer 
120:1355, 2007) by independent laboratories around the world have un-
equivocally demonstrated that RRM1 is the dominant molecular deter-
minant of gemcitabine efﬁcacy in vitro, in experimental animals, and in 
patients. Thus RRM1 expression in lung cancer patients is a prognostic 
marker; i.e., high levels are associated with good outcome independent 
of therapy; and a predictive marker; i.e., high levels are associated with 
resistance to therapy that is gemcitabine-based. Prospective multi-in-
stitutional clinical trials have been initiated with the goal to utilize this 
knowledge for therapeutic decision making.
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Unlike some tumor types, the majority of the common solid tumors ap-
pear not to be driven by single dominant targetable pathways. Instead, 
diseases such as lung cancer are likely to be much more complex and 
heterogeneous, with many distinct and overlapping subsets of tumors 
within the class, each of which will demand an in depth analysis to 
deﬁne the optimal therapeutic approach. These groups are starting to be 
deﬁned by multiple technologies, and the simplest example is the small 
subset of patients with tumors expressing mutant EGFR, who achieve 
substantial clinical beneﬁt from minimally toxic targeted therapy. Even 
for this small subset of patients with mutant epidermal growth factor 
receptors (EGFR), multiple resistance mechanisms have emerged re-
quiring different salvage strategies. There also appears to be a group of 
patients without EGFR mutations who experience clinically signiﬁcant 
